Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

<div>The meta-analysis results for various incidence rates after afatinib treatment in advanced NSCLC with EGFR mutation: (a) the incidence rate of diarrhea; (b) the incidence rate of mucositis; (c) the incidence rate of skin rashes; and (d) the incidence rate of paronychia.</div>

Journal of Oncology

fig4

Figure 4

Figure 4: Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 

Figure 4 | Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 